Related Experiment Video
Updated: Aug 13, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Radiolabelled somatostatin analog therapy in prostate cancer: current status and future directions
1Nuclear Medicine Service, Department of Radiology, New Jersey Medical School, University of Medicine & Dentistry of New Jersey, H-141, 150 Bergen Street, Newark, NJ 07101, USA. liuyl@umdnj.edu
Abstract:
Natural somatostatin is characterized as an inhibitory peptide and had anti-neoplastic actions. The effect of somatostatin is mediated via specific somatostatin receptors (SSTRs). Clinical trials have demonstrated therapeutic applications of radionuclide labeled somatostatin analogues in many tumors bearing the receptors. In prostate cancer, significance of neuroendocrine cells remains unclear, there were conflicting data about occurrence and localization of SSTRs. Therefore, radionuclide labeled somatostatin analog therapy is not applied to prostate cancer clinically, experimental trials with non-radioactive analogues have been disappointing. More efforts need to be made for evaluation of potential applications of somatostatin analog therapy in prostate cancer, for example, transfection of the receptor gene to increase binding of analogues to the tumor cells, improvement of radionuclide delivery and combinations of different therapeutic modalities.
Insights
Somatostatin analogues show anti-cancer effects by targeting somatostatin receptors (SSTRs). However, their use in prostate cancer is limited due to unclear SSTR roles and disappointing trial results.
Area of Science:
- Endocrinology
- Oncology
- Nuclear Medicine
Background:
- Somatostatin is an inhibitory peptide with anti-neoplastic properties.
- Its effects are mediated through somatostatin receptors (SSTRs).
- Radionuclide-labeled somatostatin analogues are clinically used for receptor-bearing tumors.
Purpose of the Study:
- To evaluate the potential of somatostatin analogue therapy in prostate cancer.
- To address the unclear role of neuroendocrine cells and SSTRs in prostate cancer.
- To investigate reasons for the limited clinical application of this therapy in prostate cancer.
Main Methods:
- Review of existing clinical trial data and experimental findings.
- Analysis of the significance and localization of somatostatin receptors in prostate cancer.
- Exploration of potential strategies to enhance somatostatin analogue efficacy.
Main Results:
- Conflicting data exists regarding the occurrence and localization of SSTRs in prostate cancer.
- Non-radioactive analogue trials in prostate cancer have yielded disappointing results.
- Radionuclide-labeled somatostatin analogue therapy is not currently applied clinically for prostate cancer.
Conclusions:
- Further research is needed to establish somatostatin analogue therapy for prostate cancer.
- Strategies like receptor gene transfection and improved radionuclide delivery may enhance efficacy.
- Combination therapies hold potential for future applications in prostate cancer treatment.
More Related Videos
08:55A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
10:33Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
Published on: April 25, 2025
